Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEOD001 phase 2 study in AL amyloidosis with hepatic involvement
2016-000489-50Phase 2Terminated
- Sponsor
- IRCCS San Matteo Foundation
- Start
- Jun 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of birtamimab in light-chain amyloidosis and Hepatic Amyloidosis, sponsored by IRCCS San Matteo Foundation. Primary endpoint: Hepatic best response from Screening/Baseline to Month 6. Started Jun 2021; status: terminated.
02
Drugs
birtamimab
03
Conditions
light-chain amyloidosisHepatic Amyloidosis
Beyond the preview
Go deeper on 2016-000489-50.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000489-50.